Fig 5.

Depletion of FGF9 suppresses tumorigenicity of TRAMP tumor cells. A. Real-time RT-PCR analyses for Fgf9 expression in TRAMP-C2 cells and FGF9 depleted TRAMP-C2 cells. B. Subcutaneous grafts of TRAMP-C2/UGM cells with or without FGF9 depletion in TRAMP-C2 cells. Graft weight is mean ± sd from 3 grafts per group. C. H&E and immunostaining of graft sections with the indicated antibodies. D. Masson Trichrome staining of prostate sections of 64-month-old TRAMP or F9TRAMP mice, demonstrating excessive collagen deposition in the stromal compartment of F9TRAMP mice. E. Co-staining of α-smooth muscle actin and vimentin in 4-month-old TRAMP and F9TRAMP prostates. UGM, urogenital mesenchymal cells; Ctrl, control; KD, knockdown; scale bar, 50 µm.